Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $51.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 53.6% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (up 53.6% YoY), while the FY2025 annual figure was $70.7 million, up 47.67% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $51.8 million, down from $70.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $70.7 million in Q4 2025, with the low at $14.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $33.3 million (2022), against an average of $36.1 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 144.57% in 2022, then fell 20.13% in 2023.
• Viridian Therapeutics, Inc.\DE's Total Current Liabilities stood at $33.3 million in 2022, then fell by 20.13% to $26.6 million in 2023, then jumped by 79.74% to $47.9 million in 2024, then soared by 47.67% to $70.7 million in 2025, then decreased by 26.72% to $51.8 million in 2026.
• Business Quant data shows VRDN's Total Current Liabilities at $51.8 million in Q1 2026, $70.7 million in Q4 2025, and $50.7 million in Q3 2025.